Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by reducing glucose levels in the blood through increasing urinary glucose excretion. These medications work by inhibiting the reabsorption of glucose in the kidneys, leading to more glucose being excreted in the urine. SGLT2 inhibitors have been shown to be effective in lowering blood sugar levels, improving insulin sensitivity, and promoting weight loss. They have also been associated with cardiovascular benefits and reduced risk of heart failure in diabetic patients. Common SGLT2 inhibitors include empagliflozin, canagliflozin, and dapagliflozin. These medications are typically taken orally and are often prescribed in combination with other diabetes medications. Overall, SGLT2 inhibitors are an important and effective treatment option for individuals with type 2 diabetes, particularly for those who are struggling to achieve glycemic control with other therapies.